Pfizer Inc. (NYSE: PFE) and ReViral Ltd. announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).
Pfizer to acquire ReViral and its respiratory syncytial virus therapeutic candidates
April 7, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022